Af­ter a months-long halt on pro­duc­tion, Emer­gent is back up and run­ning in Bal­ti­more

It’s been a long time since Emer­gent BioSo­lu­tions has been able to pro­duce Covid-19 vac­cines at its Bal­ti­more Bayview plant, but the FDA has giv­en the com­pa­ny the go-ahead to re­sume pro­duc­tion, a com­pa­ny spokesman con­firmed Thurs­day morn­ing in an email to End­points News.

The news comes two months af­ter the com­pa­ny said it was near a deal to re­sume. In a House sub­com­mit­tee meet­ing in June, CEO Bob Kramer said that his com­pa­ny was pre­pared to re­sume man­u­fac­tur­ing im­me­di­ate­ly af­ter it re­ceived the go-ahead from the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER